关键词: 前列腺癌, 老年, 89锶, 99锝-亚甲基二膦酸盐, 骨转移, 唑来膦酸

Abstract: ［Abstract］ Objective To evaluate the clinical efficacy and safety of 89Sr， zoledronic acid and 99Tc?MDP for treating the elderly patients with prostate cancer and bone metastases. Methods A total of 53 elderly patients with prostate cancer and bone metastases from January 2017 to January 2018 were included in the study for a retrospective analysis. The patients were divided into three groups： 89Sr group （A group）， zoledronic acid group （B group） and 99Tc?MDPgroup （C group）. The clinical value about three?way therapy were evaluated on bone pain relief rate， number of bone metastases and adverse events. Results In early stage of treatment， patients with bone pain relief got more benefit form group A. However， the differences between the three groups decreased after 6 months of treatment， and there was no significant difference among the three groups after 12 months （P>0.05）. The relief of severe pain in A and B group looked better than that of moderate pain on extreme pain， which was not statistically significant （P>0.05）. Group C was more efficient for moderate pain. Elimination of bone lesions： Group A was higher than group B， and Group B was higher than group C， but there were no significant difference （P>0.05）. The three groups were more efficient in the patients of bone?lesion number ≥10， which had no statistical difference （P>0.05）. Adverse events： Myelosuppression of 89Sr and fever of zoledronic acid in elderly patients had difference （P<0.05） from other groups. Anther adverse reactions did not significantly. Conclusion 89Sr， zoledronic acid and 99Tc?MDP were effectively improve pain palliation and could obviously repair the bone destruction caused by metastases. To be extra careful about myelosuppression of 89Sr in elderly patients. The elderly patients had more suffering by use of long?time intravenous for 99Tc?MDP. Although treatment by zoledronic acid would cause fever， it could self?relief. zoledronic acid was clinical recommendation.

Key words: zoledronic acid, prostate cancer, 89Sr, 99Tc?MDP, bone metastases, elderly